Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 232,062,283 papers from all fields of science
Search
Sign In
Create Free Account
GED0301
Known as:
mongersen
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Oligonucleotides
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD: When Trial Design Is as Important as Disease Therapy.
M. Bewtra
,
G. Lichtenstein
American Journal of Gastroenterology
2020
Corpus ID: 213192535
The phase II mongersen (GED-0301) trial produced unparalleled success rates in Crohn's disease and generated much hope for a…
Expand
2017
2017
PD-008 A Study of Oral Mongersen (GED-0301) on Endoscopy and Clinical Activity (Stool Frequency and Abdominal Pain) in Crohn's Disease
Feagan Brian
,
Sands Bruce
,
+4 authors
Colombel Jean-Frédéric
2017
Corpus ID: 56998790
Background: Mongersen (GED-0301) is an antisense oligodeoxynucleotide that is complementary to the sequence of the messenger RNA…
Expand
2017
2017
Correlation of Clinical and Endoscopic Outcomes in Patients with Active Crohn’s Disease Treated with Mongersen (GED-0301)
B. Feagan
,
J. Colombel
,
+4 authors
B. Sands
2017
Corpus ID: 80588913
2017
2017
PD-007 YI High-dose Infliximab Lowers 30-Day Colectomy Rates in Hospitalized Ulcerative Colitis Patients: A Propensity-Score Weighted Analysis
Shailja C. Shah
,
S. Naymagon
,
H. Panchal
,
B. Cohen
,
B. Sands
,
M. Dubinsky
2017
Corpus ID: 189946165
that maternal IBD affects both the offspring’s immediate and long-term morbidity, specifically congenital anomalies and…
Expand
2016
2016
Editorial: mongersen in Crohn's disease – a new contribution to the beginning of a long‐awaited therapeutic revolution?
J. Kirchgesner
,
H. Sokol
Alimentary Pharmacology and Therapeutics
2016
Corpus ID: 32915670
In a phase II trial assessing the efficacy and safety of mongersen, an oral SMAD7 anti-sense oligonucleotide for treating…
Expand
2016
2016
PC.01.3 KNOCKDOWN OF SMAD7 WITH MONGERSEN ATTENUATES COLITIS AND COLITIS-DRIVEN FIBROSIS IN MICE
R. Izzo
,
I. Marafini
,
+5 authors
G. Monteleone
2016
Corpus ID: 78658780
2015
2015
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease.
G. Monteleone
,
F. Pallone
New England Journal of Medicine
2015
Corpus ID: 52817426
2015
2015
Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?
S. Danese
,
G. Fiorino
,
L. Peyrin-Biroulet
Gastroenterology
2015
Corpus ID: 37287968
2015
2015
Therapy: Oral SMAD7 antisense oligonucleotide proves effective for Crohn's disease
K. Ray
Nature Reviews Gastroenterology &Hepatology
2015
Corpus ID: 6155421
2015
2015
Morbus Crohn – Patienten profitieren von Mongersen
M. Hofmann-Assmus
Zeitschrift für Gastroenterologie - German…
2015
Corpus ID: 79173059
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE